Levofloxacin in the Medical Management of Community-acquired Pneumonia (Interview with Prof. Andy I. M. Hoepelman)

20 June, 2018

drphoto

Question

CAP – Defining the Diagnosis

Q01	Definition and diagnosis of community-acquired pneumonia (CAP)
Q02	Investigating the CAP patient – what is required?
Q03	Risk factors for a poor prognosis

The Pathogens Responsible for CAP and their Antimicrobial Susceptibility

Q04	Bacterial etiology of CAP
Q05	The role of atypicals in CAP
Q06	Predicting the pathogen in CAP based on severity of disease
Q07	Which antimicrobials should be used in CAP?
Q08	Resistance in respiratory tract infections: the incidence of penicillin-resistant Streptococcus pneumoniae (PRSP) in Europe
Q09	Macrolide resistance – how has it changed CAP therapy?

Pharmacokinetic Features of Fluoroquinolones

Q10	Major changes in empiric management of CAP
Q11	Predicting fluoroquinolone activity based on pharmacodynamic features
Q12	Pharmacokinetic/pharmacodynamic variables for respiratory fluoroquinolones against Streptococcus pneumoniae

International Society Guidelines for the Management of CAP

Q13	International guidelines for outpatient treatment of CAP – European Respiratory Society (ERS), Infectious Diseases Society of America (IDSA), Canadian Infectious Disease Society/Canadian Thoracic Society (CIDS/CTS)
Q14	International guidelines for outpatient treatment of CAP – Center for Disease Control and Prevention (CDCP), American Thoracic Society (ATS)
Q15	International guidelines for inpatient treatment of CAP – ERS, IDSA, CIDS/CTS
Q16	International guidelines for inpatient treatment of CAP – ATS, CDCP

Levofloxacin – Preeminent Respiratory Fluoroquinolone

Q17	Clinical trials of levofloxacin in CAP
Q18	Levofloxacin versus azithromycin/ceftriaxone in CAP
Q19	Safety of levofloxacin compared to other fluoroquinolones
Q20	Cost-effectiveness data for levofloxacin in CAP